AGITATION IN PATIENTS WITH DEMENTIA OF THE ALZHEIMER'S TYPE
Clinical trials for AGITATION IN PATIENTS WITH DEMENTIA OF THE ALZHEIMER'S TYPE explained in plain language.
Never miss a new study
Get alerted when new AGITATION IN PATIENTS WITH DEMENTIA OF THE ALZHEIMER'S TYPE trials appear
Sign up with your email to follow new studies for AGITATION IN PATIENTS WITH DEMENTIA OF THE ALZHEIMER'S TYPE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Alzheimer's agitation drug safety trial ends early
Disease control TerminatedThis study tested the long-term safety of AXS-05, a combination of dextromethorphan and bupropion, for treating agitation in people with Alzheimer's disease. It enrolled 139 participants who had completed earlier studies. The trial was terminated early, so the full safety picture…
Matched conditions: AGITATION IN PATIENTS WITH DEMENTIA OF THE ALZHEIMER'S TYPE
Phase: PHASE3 • Sponsor: Axsome Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Alzheimer's agitation drug trial halted early
Disease control TerminatedThis study tested a drug called AVP-786 to see if it could safely reduce agitation in people with Alzheimer's dementia over the long term. It was an extension of earlier studies, enrolling over 1,100 participants who had already completed a prior trial. However, the study was ter…
Matched conditions: AGITATION IN PATIENTS WITH DEMENTIA OF THE ALZHEIMER'S TYPE
Phase: PHASE3 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC